A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

Documenti analoghi

• Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
  di: Sinxadi, Phumla, et al.
  Pubblicazione: (2020)
• Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
  di: Paquet, Tanya, et al.
  Pubblicazione: (2017)
• A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
  di: McCarthy, James S., et al.
  Pubblicazione: (2019)
• Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics
  di: Ghidelli-Disse, Sonja, et al.
  Pubblicazione: (2014)
• Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
  di: Abd‐Rahman, Azrin N., et al.
  Pubblicazione: (2020)